Merck and the pharmaceutical industry are headline news today. Controversies over public safety, prices, and the ability of the industry to develop the new drugs and vaccines that society needs have been covered worldwide. Roy Vagelos, who was head of research and then CEO at Merck from the mid-1970s through the early 1990s, addresses these issues here. Success with targeted research started Merck on a path that would lead to a series of block-buster therapies that carried the firm to the top of the global industry in the 1990s and Vagelos into the top position at the company. Trained as a physician and scientist, he had to learn how to run a successful business while holding to the highest principles of ethical behavior. He was not always successful. He and his co-author explain where and why he failed to achieve his goals and carefully analyze where he succeeded.

In Medicine, Science, and Merck, the authors trace the careers of a son of Greek immigrants as he mastered three professions and ultimately became the Chief Executive Officer of America’s most admired corporation - the multinational, pharmaceutical giant, Merck & Co., Inc. As the authors show, there was hope even for a wise-cracking kid living through the hard times of the 1930s. Education brought out the scholar in Roy Vagelos, who left his family’s small restaurant to attend the University of Pennsylvania, Columbia’s Medical School, and Massachusetts General Hospital in Boston. At NIH, he mastered biochemistry; at Washington University he became a distinguished science administrator; and at Merck, he headed the pharmaceutical industry’s most innovative laboratory and then became its CEO. Throughout, he never lost touch with his family values, his intense desire to help others, or his faith in the partnership principle and the competition that makes it work.

Merck and the pharmaceutical industry are headline news today. Controversies over public safety, prices, and the ability of the industry to develop the new drugs and vaccines that society needs have been covered worldwide. Roy Vagelos, who was head of research and then CEO at Merck from the mid-1970s through the early 1990s, addresses these issues here. Success with targeted research started Merck on a path that would lead to a series of block-buster therapies that carried the firm to the top of the global industry in the 1990s and Vagelos into the top position at the company. Trained as a physician and scientist, he had to learn how to run a successful business while holding to the highest principles of ethical behavior. He was not always successful. He and his co-author explain where and why he failed to achieve his goals and carefully analyze where he succeeded.